Please use this identifier to cite or link to this item:
Title: Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells
Authors: Gomes-da-Silva, Lígia C. 
Ramalho, José S. 
Lima, M. C. P. de 
Simões, Sérgio 
Moreira, João N. 
Keywords: Nanotechnology; siRNA; PLK1; Gene silencing; Paclitaxel; Prostate cancer
Issue Date: 2013
Publisher: Elsevier B.V.
Serial title, monograph or event: European Journal of Pharmaceutics and Biopharmaceutics
Volume: 85
Issue: 3 Part A
Abstract: We have previously described the development of novel sterically stabilized F3-targeted pH-sensitive liposomes, which exhibited the ability to target both cancer and endothelial cells. Herein, the therapeutic potential of those liposomes was assessed upon encapsulation of a siRNA against a well-validated molecular target, PLK1. Treatment of prostate cancer (PC3) and angiogenic endothelial (HMEC-1) cells with F3-targeted liposomes containing anti-PLK1 siRNA resulted in a significant decrease in cell viability, which was mediated by a marked PLK1 silencing, both at the mRNA and protein levels. Furthermore, pre-treatment of PC3 cells with F3-targeted liposomes containing anti-PLK1 siRNA enabled a 3-fold reduction of paclitaxel IC50 and a 2.5-fold augment of the percentage of cancer cells in G2/mitosis arrest, which ultimately culminated in cell death. Overall, the F3-targeted nanocarrier containing an anti-PLK1 siRNA might constitute a valuable system for prostate cancer treatment, either applied in a single schedule or combined with conventional chemotherapy.
DOI: 10.1016/j.ejpb.2013.04.007
Rights: openAccess
Appears in Collections:FCTUC Ciências da Vida - Artigos em Revistas Internacionais

Files in This Item:
File Description SizeFormat
1-s2.0-S0939641113001537-main(1).pdf1.19 MBAdobe PDFView/Open
Show full item record


checked on Nov 11, 2022

Citations 5

checked on May 2, 2023

Page view(s)

checked on Feb 27, 2024


checked on Feb 27, 2024

Google ScholarTM




Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.